Sleep Optimization Stack
DSIP + Ipamorelin
Improve sleep quality, deepen sleep architecture, and maximize overnight growth hormone release
Overview
Combines the delta sleep-inducing peptide (DSIP) for improving sleep architecture with Ipamorelin to capitalize on the natural GH pulse that occurs during deep sleep. DSIP promotes slow-wave (delta) sleep patterns, while Ipamorelin timed before bed amplifies the nocturnal GH surge that drives overnight recovery and tissue repair.
Component Peptides
Sleep architecture modulator — promotes delta wave sleep patterns and may modulate cortisol rhythms
Selective GH secretagogue — amplifies natural nocturnal GH pulse for enhanced overnight recovery
Expected Timeline
Improved sleep quality often noticed within 2-5 days. Deeper, more restorative sleep reported within 1-2 weeks. Recovery improvements correlated with GH effects at 4-6 weeks.
Safety Notes
- DSIP research is limited — long-term safety data is sparse
- Do not combine with other sleep medications without physician guidance
- Ipamorelin must be taken on empty stomach for optimal GH release
- May cause vivid dreams, especially in the first few days
- Both peptides are WADA-prohibited
Bloodwork Recommendations
- IGF-1 levels (baseline and follow-up)
- Cortisol (AM and PM — DSIP may modulate cortisol rhythm)
- Fasting glucose
- Consider a sleep study for baseline objective sleep data
Contraindications
- Sleep apnea (untreated)
- Active cancer
- Use of sedative medications or alcohol
- Pregnancy or breastfeeding
- Competitive athletes (WADA-prohibited)
Evidence Assessment
DSIP was discovered in the 1970s and has been the subject of some human studies showing effects on sleep patterns, but research is limited and inconsistent. Some studies failed to replicate sleep-inducing effects. Ipamorelin has better-established GH-releasing properties from clinical trials. The combination is based on community reports and theoretical synergy rather than clinical evidence.
References
- Graf MV, et al. "Delta sleep-inducing peptide (DSIP): a review." Neurosci Biobehav Rev. 1986;10(2):83-93.
- Schneider-Helmert D, et al. "Effects of DSIP on human sleep behavior." Eur Neurol. 1981;20(4):269-272.
- Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998.
Research Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All products referenced are for in vitro laboratory research use only. Consult a qualified healthcare professional before beginning any research protocol.